Literature DB >> 1515658

Androgen profile in patients with pancreatic carcinoma.

C Sperti1, B Bonadimani, P Guolo, C Militello, F Cappellazzo, C Pasquali, S Pedrazzoli.   

Abstract

Serum testosterone, free testosterone and androstenedione levels were measured in 28 male patients with pancreatic cancer and compared with the values obtained from 28 male patients with chronic pancreatitis, 29 with gastrointestinal malignancies and 41 healthy controls. Mean total testosterone values were significantly lower in the pancreatic cancer group when compared to chronic pancreatitis and healthy controls. Total testosterone concentrations were also significantly lower in patients with gastrointestinal malignancies when compared to healthy controls. No difference was found in free testosterone and androstenedione levels in the four groups of patients. Total testosterone serum levels correlated significantly with poor nutritional status. This study confirms low testosterone levels in patients with pancreatic cancer, but provides no evidence to support a direct relationship between pancreatic cancer and testosterone metabolism.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1515658

Source DB:  PubMed          Journal:  Ital J Gastroenterol        ISSN: 0392-0623


  2 in total

1.  Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients.

Authors:  Andrew J Weickhardt; Robert C Doebele; W Thomas Purcell; Paul A Bunn; Ana B Oton; Micol S Rothman; Margaret E Wierman; Tony Mok; Sanjay Popat; Julie Bauman; Jorge Nieva; Silvia Novello; Sai-Hong Ignatius Ou; D Ross Camidge
Journal:  Cancer       Date:  2013-04-12       Impact factor: 6.860

2.  Interaction of gonadal status with systemic inflammation and opioid use in determining nutritional status and prognosis in advanced pancreatic cancer.

Authors:  Richard J E Skipworth; Alastair G W Moses; Kathryn Sangster; Catharine M Sturgeon; Anne C Voss; Marie T Fallon; Richard A Anderson; James A Ross; Kenneth C H Fearon
Journal:  Support Care Cancer       Date:  2010-03-12       Impact factor: 3.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.